Impact of SF3B1 mutation in myelofibrosis

Jayastu Senapati; Srdan Verstovsek; Lucia Masarova; Naveen Pemmaraju; Keyur P. Patel; Guillermo Montalban-Bravo; Sherry A. Pierce; Lingsha Zhou; Guillermo Garcia-Manero; Hagop M. Kantarjian; Prithviraj Bose

doi:10.1080/10428194.2022.2095629

Impact of SF3B1 mutation in myelofibrosis

Jayastu Senapati, Srdan Verstovsek, Lucia Masarova, Naveen Pemmaraju, Keyur P. Patel, Guillermo Montalban-Bravo, Sherry A. Pierce, Lingsha Zhou, Guillermo Garcia-Manero, Hagop M. Kantarjian, Prithviraj Bose

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	2701-2705
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	63
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2022.2095629
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2022.2095629

Cite this

@article{ab5f7ee297d740aea79831030e9fc4e8,

title = "Impact of SF3B1 mutation in myelofibrosis",

author = "Jayastu Senapati and Srdan Verstovsek and Lucia Masarova and Naveen Pemmaraju and Patel, {Keyur P.} and Guillermo Montalban-Bravo and Pierce, {Sherry A.} and Lingsha Zhou and Guillermo Garcia-Manero and Kantarjian, {Hagop M.} and Prithviraj Bose",

note = "Funding Information: This work was supported, in part, by the MD Anderson Cancer Center Support Grant, P30 CA016672, from the National Cancer Institute (National Institutes of Health). Funding Information: SV received research grant/funding from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Genentech, Blueprint, Novartis, Sierra, Pharma Essentia, Astrazeneca, Italfarmaco, and Protagonist Therapeutics; received consulting fees from Constellation, Sierra, Incyte, Novartis, Celgene, and Bristol Myers Squibb. NP received consulting fees/honoraria from Pacylex, Celgene, Stemline, Incyte, Novartis, Mustang Bio, Roche Diagnostics, and LFB and research funding from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, Affymetrix, and Sager Strong Foundation. GMB received research funding from IFM Therapeutics. HK received research grants and honoraria from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer and Sanofi; honoraria from Actinium (Advisory Board), Adaptive Biotechnologies, Aptitude Health, Bio Ascend, Delta Fly, Janssen Global, Oxford Biomedical and Takeda Oncology. PB recived honoraria from Incyte, BMS, CTI BioPharma, Sierra Oncology, Constellation (Morphosys), Blueprint Medicines, Novartis, Pharma Essentia, Karyopharm, and Kartos, and research support from Incyte, BMS, CTI BioPharma, Cogent, Blueprint Medicines, Pfizer, Astellas, NS Pharma, Promedior, Kartos and Constellation (Morphosys). ",

year = "2022",

doi = "10.1080/10428194.2022.2095629",

language = "English (US)",

volume = "63",

pages = "2701--2705",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Impact of SF3B1 mutation in myelofibrosis

AU - Senapati, Jayastu

AU - Verstovsek, Srdan

AU - Masarova, Lucia

AU - Pemmaraju, Naveen

AU - Patel, Keyur P.

AU - Montalban-Bravo, Guillermo

AU - Pierce, Sherry A.

AU - Zhou, Lingsha

AU - Garcia-Manero, Guillermo

AU - Kantarjian, Hagop M.

AU - Bose, Prithviraj

N1 - Funding Information: This work was supported, in part, by the MD Anderson Cancer Center Support Grant, P30 CA016672, from the National Cancer Institute (National Institutes of Health). Funding Information: SV received research grant/funding from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Genentech, Blueprint, Novartis, Sierra, Pharma Essentia, Astrazeneca, Italfarmaco, and Protagonist Therapeutics; received consulting fees from Constellation, Sierra, Incyte, Novartis, Celgene, and Bristol Myers Squibb. NP received consulting fees/honoraria from Pacylex, Celgene, Stemline, Incyte, Novartis, Mustang Bio, Roche Diagnostics, and LFB and research funding from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi-Sankyo, Affymetrix, and Sager Strong Foundation. GMB received research funding from IFM Therapeutics. HK received research grants and honoraria from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer and Sanofi; honoraria from Actinium (Advisory Board), Adaptive Biotechnologies, Aptitude Health, Bio Ascend, Delta Fly, Janssen Global, Oxford Biomedical and Takeda Oncology. PB recived honoraria from Incyte, BMS, CTI BioPharma, Sierra Oncology, Constellation (Morphosys), Blueprint Medicines, Novartis, Pharma Essentia, Karyopharm, and Kartos, and research support from Incyte, BMS, CTI BioPharma, Cogent, Blueprint Medicines, Pfizer, Astellas, NS Pharma, Promedior, Kartos and Constellation (Morphosys).

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85133427210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133427210&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2095629

DO - 10.1080/10428194.2022.2095629

M3 - Letter

C2 - 35787095

AN - SCOPUS:85133427210

SN - 1042-8194

VL - 63

SP - 2701

EP - 2705

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Impact of SF3B1 mutation in myelofibrosis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this